Navigation Links
FDA Wants New Diabetes Drugs Tested for Heart Risks
Date:12/17/2008

Companies must now show their drugs don't increase chances of cardiac trouble

WEDNESDAY, Dec. 17 (HealthDay News) -- The U.S. Food and Drug Administration is now asking all companies looking for approval of new type 2 diabetes medications to undertake studies that determine whether they cause cardiovascular problems.

This new guidance document, announced Wednesday, comes on the heels of reports that two commonly prescribed blood sugar-lowering drugs already on the market, Avandia and Actos, increase the risk of heart failure and, in the case of Avandia, increase the risk of heart attack.

"The guidance document will help industry evaluate the cardiovascular risk associated with new therapies under development to treat type 2 diabetes," Dr. Mary Parks, director of the Division of Metabolism and Endocrinology Products in FDA's Center for Drug Evaluation and Research said during a Wednesday afternoon teleconference.

Parks noted that diabetic patients are already at an increased risk for cardiovascular problems. But the agency believes it's important to insure that new drugs don't compound the risk further, she said. More than 23 million people in the United States have been diagnosed with type 2 diabetes.

The new guidance reflects the decision of the FDA's Endocrinologic and Metabolic Drugs Advisory Committee, which in July called for studies of the cardiovascular risks of new diabetic drugs.

According to the new guidance, companies looking to have new diabetes drugs approved by the FDA must submit data from phase II and phase III trials that show these drugs are not associated with an "unacceptable risk" of cardiovascular disease, Parks said.

Parks noted that these new requirements mean that companies will have to enroll more patients in clinical trails than in the past, especially more older patients who are already at risk for heart disease.

Trials assessing cardiovascular risks will have to go on for at least a year, Parks said. "The trials have to be of an adequate duration so that we can get a sense of long-term risk," she explained.

The change in the approval process does mean that it will take longer for new drugs to reach the market. "It's safe to assume that requiring a longer duration of trials, and a bolstering of the sample size, that it will add some years to the clinical development program," Parks said.

The FDA has sent 100 to 150 letters to companies with new diabetes products under development to alert them of the new guidance, which takes effect immediately, Parks said.

This guidance document does not affect drugs already on the market. These drugs will be the subject of another guidance document, Parks said. When that document will be released isn't known. "It's on our to-do list," she said.

More information

For more information on diabetes, visit the U.S. National Institute on Diabetes and Kidney Diseases .



SOURCES: Dec. 17, 2008, teleconference with Mary Parks, M.D., director, Division of Metabolism and Endocrinology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. New Poll Shows Public Worried About Medicare Cuts Impact on Seniors, Boomers - Wants Congress To Act
2. Adverse housing conditions contribute to diabetes risk
3. RAND finds cases of undiagnosed diabetes drop sharply
4. UCLA researchers identify markers that may predict diabetes in still-healthy people
5. Diabetes appears to increase risk of death for patients with acute coronary syndromes
6. Discovery of sugar sensor in intestine could benefit diabetes
7. Despite overeating, morbidly obese mice gain protection against diabetes
8. Heart Attack Boosts Diabetes Risk
9. Obesity Doesnt Always Equal Diabetes
10. Sugary Sodas High in Diabetes-Linked Compound
11. Treating diabetes during pregnancy can break link to childhood obesity
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Wants New Diabetes Drugs Tested for Heart Risks
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at ... of the most popular and least understood books in the Holy Scriptures, Revelation. The ... that have baffled scholars for centuries. Many have tossed it off as mere rubbish, ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and ... of published author, William Nowers. Captain Nowers and his wife, Millie, have six ... years in the Navy. Following his career as a naval aviator and carrier ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s to ... and tested to meet the highest standard. , These products are also: ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
(Date:10/12/2017)... ... 12, 2017 , ... On Saturday, October 21, the Health & Wellness Center ... to raise money for the American Heart Association Heart Walk. Teams of up to ... together to keep their treadmills moving for 5 hours. Treadmills will start at 7:00 ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... 2017 AVACEN Medical , Inc. (AVACEN) announced ... 2017 New Product Innovation Award for Its fibromyalgia pain ... secondary medical device market research by Frost & Sullivan,s industry ... drug-free pain relief product, the AVACEN 100, offers a safe ... widespread pain. ...
(Date:10/12/2017)... , Oct. 12, 2017 West ... in innovative solutions for injectable drug administration, today announced ... the market opens on Thursday, October 26, 2017, and ... results and business expectations at 9:00 a.m. Eastern Time. ... or 253-336-8738 (International). The conference ID is 94093362. ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ... on fulfilling the promise of precision medicine, today announced ... joined Caris, Precision Oncology Alliance™ (POA) as its 17 ... centers, the St. Jude Crosson Cancer Institute will help ... the use of tumor profiling, making cancer treatment more ...
Breaking Medicine Technology: